EMA Refused: Sovrima (idebenone) — Centocor B.V.

View source ↗

Summary

The EMA refused the marketing authorization for Sovrima (idebenone) by Centocor B.V. for Friedreich ataxia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• Sovrima (idebenone)

Snippet

Status: Refused. Therapeutic area: Friedreich Ataxia. MAH: Centocor B.V.. Decision date: 31/12/2009. Orphan medicine